Home – Page 31 – The Cancer Letter

Issue 10 - Mar 8, 2019

TCL45-10 (467 downloads)

Trump’s proposal for pediatric cancer has NCI envisioning the first data federation of its kind
In anticipation of an infusion of funds from Congress, NCI is developing a blueprint for a comprehensive cancer data federation—starting with pediatric cancer.
Conversation with The Cancer Letter
Sharpless: With $500 million, NCI can create data federation that would change research in childhood cancer
If this effort is highly successful for childhood cancer, then we’ll broaden the efforts to other cancers next. This is an important first step in learning how useful radical data sharing and aggregation can be.
Conversation with The Cancer Letter
CHOP’s Resnick: Big data will transition from research to the standard of care in the clinic
It’s extremely exciting to hear and see both the NCI and the administration and other community partners and patient groups really coming together and reconsidering, ‘What are the unmet needs that can inform in new ways through new approaches of integration?
Conversation with The Cancer Letter
St. Jude’s Roberts: “No single institution can maximize cures and minimize toxicities alone”
Historically, cancer research drug development has largely been focused upon adult cancers with drugs trickling down to pediatric trials over time. But we now know that 55 percent of the driver mutations are unique to childhood cancers. So, relying upon that old model is not going to serve children well.
Guest Editorial
Needed: A fully funded data federation for pediatric cancer with deep genomic sequencing and clinical records
It was a thrilling moment for me when, sitting on my living room couch, listening to the State of the Union address, I heard the president say:
“Many childhood cancers have not seen new therapies in decades. My budget will ask the Congress for $500 million over the next 10 years to fund this critical life-saving research.”
Gottlieb resigns at FDA, recommends Sharpless as successor
Scott Gottlieb has submitted a letter of resignation from his job as FDA commissioner, reportedly recommending that NCI Director Ned Sharpless be appointed as his successor at the agency.
In Brief
- Raymond DuBois receives AACR Margaret Foti Award
- Charles Sawyers to present AACR Princess Takamatsu memorial lecture
- Alberto Mantovani receives Pezcoller Foundation-AACR Award
- Jeffrey Bluestone to receive AACR-Irving Weinstein Foundation lectureship award
- Manuel Hidalgo named chief of hematology and medical oncology at Weill Cornell
- Greg Delgoffe to receive Sy Holzer Endowed Immunotherapy Research Fund
Funding Opportunities
FDA Oncology Center of Excellence publishes research contract opportunities
The FDA Oncology Center of Excellence seeks white papers to award contracts for oncology regulatory science research through a Broad Agency Announcement, FDABAA-19-00123.
Clinical Roundup
- Genentech submits sNDA for Venclexta plus Gazyva for previously untreated CLL
- Study: AI may perform as well as radiologists
Drugs & Targets
- Paige.AI receives FDA Breakthrough Device designation
- Lynparza receives positive EU CHMP opinion in breast cancer
- Breast Cancer Index receives expanded Medicare coverage
NCI Trials
NCI Trials for March
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Issue 9 - Mar 1, 2019

TCL45-09 (234 downloads)

ODAC gives thumbs down to single-arm trial of two-drug combination for multiple myeloma
Committee focuses on meaning of equipoise, accelerated approval, confirmatory trials
It’s not just the absence of a randomized trial that prompted the FDA Oncologic Drugs Advisory Committee to recommend against an accelerated approval of the Karyopharm Therapeutics Inc. drug selinexor for late-stage multiple myeloma.
FDA tightens regulation of robotic devices in minimally invasive surgery for cancer
Device manufacturers looking to market surgical tools for use in the prevention or treatment of cancer may now be required to study long-term oncologic endpoints in surgical trials, according to a safety communication published by FDA on Feb. 28.
In Brief
- NCORP networks to take part in NCI’s Moonshot Tissue Procurement Protocol
Conversation with The Cancer Letter
CDC: HPV vaccine dramatically reduced HPV-related cervical precancers over 6 years
The number of cases of HPV+ cervical precancers has dropped by 21 percent from 2008 to 2014, according to a survey by the Centers for Disease Control and Prevention.
Clinical Roundup
- BRACAnalysis CDx test identified patients with pancreatic cancer who benefitted from Olaparib
- PET scans show biomarkers could spare some breast cancer patients from chemotherapy
- Medicaid expansion in Kentucky led to more screening and higher CRC survival
- Study shows annual non-invasive stool test effective for colon cancer screening
- Lab-grown mini tumors could help identify personalized treatments for people with rare cancers
- Inherited mutations may play a role in development of pancreatic cancer
Drugs & Targets
- FDA approves new formulation of Herceptin
- FDA approves Lonsurf with GEJ adenocarcinoma

Issue 8 - Feb 22, 2019

TCL45-08 (235 downloads)

NCI invites scientists to step up competition for $173 million set-aside for commercialization
NCI would like you to know that it has a pot of money for commercialization projects—please apply.
Together, the institute’s Small Business Innovation Research and Small Business Technology Transfer programs are giving out $173 million in fiscal 2019. At NIH, these programs gave out $1.145 billion.
Conversation with The Cancer Letter
Caryn Lerman on leading USC Norris: Team science is where breakthroughs emerge
Caryn Lerman was named director of USC Norris Comprehensive Cancer Center.
When she reports to work at USC on March 15, Lerman will be the only behavioral scientist to lead an NCI-designated cancer center. She also will hold the position of professor of psychiatry and the behavioral sciences at the Keck School of Medicine of USC.
In Brief
- NCI’s Rosenberg to receive Szent-Györgyi prize
- Vale named executive director of HHMI Janelia Research Campus
- Baylor consolidates cancer center clinics on new McNair Campus
- Merck to acquire Immune Design
- Doubrava joins Fox Chase
Funding Opportunities
ASCO invites applications for research based on data from CancerLinQ Discovery
The American Society of Clinical Oncology is inviting applications for research grants for projects that use data from CancerLinQ Discovery, an offering of ASCO’s CancerLinQ initiative, as a source.
Clinical Roundup
- Guidelines recommend genetic testing for all people with breast cancer
- Keytruda + Inlyta reduced risk of death by nearly half compared to sunitinib in RCC
- OS and PFS for Keytruda in hepatocellular carcinoma did not meet statistical significance
- Merck expands immuno-oncology program with three phase III trials in prostate cancer
- Opdivo + Yervoy shows response in pre-treated patients with prostate cancer
- Janssen announces preliminary results from phase II GALAHAD in prostate cancer
- Roswell Park researchers identify protein that contributes to racial disparities in prostate cancer
- AVEO Oncology announces TIVO-3 trial topline results
- SCLC may respond to combination of immunotherapy and DNA damage repair inhibitors
- Study finds melanoma brain metastases immunosuppressive with treatment-resistant metabolism
- Dasatinib enhances response to checkpoint inhibitors, study finds
- Integrating heart disease and cancer care could reduce overall health care costs
- CASSINI Trial publishes data on preventing blood clots in cancer patients
Drugs & Targets
- FDA approves Keytruda for adjuvant treatment of melanoma
- FDA accepts IND for TR1801-ADC, an ADC targeting cMet positive solid tumors
- FDA grants priority review to Merck’s sBLA for Keytruda monotherapy in SCLC
- FDA publishes revised draft guidance for investigational tobacco products

Page 31 of 118« First «...10 20...27 28 29 303132 33 34 35 36...50 60 70 80 90 100 110...»Last »